Qiagen N.V. (QGEN)
| Market Cap | 12.06B |
| Revenue (ttm) | 2.07B |
| Net Income (ttm) | 448.58M |
| Shares Out | 228.41M |
| EPS (ttm) | 1.92 |
| PE Ratio | 27.54 |
| Forward PE | 21.32 |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | July 30 |
| Last Price | $52.79 |
| Previous Close | $52.22 |
| Change ($) | 0.57 |
| Change (%) | 1.09% |
| Day's Open | 53.66 |
| Day's Range | 52.71 - 54.01 |
| Day's Volume | 1,335,973 |
| 52-Week Range | 45.33 - 59.00 |
Faster-than-expected vaccination uptake leads to a reduction in demand for COVID-19 testing for QIAGEN (QGEN) in Q2.
Qiagen N.V. (NYSE: QGEN) reported after the close of the market Thursday that its second-quarter revenues jumped 28% Y/Y as growth in its core product portfolio tempered, flagging non-COVID-19-related s...
Qiagen (QGEN) delivered earnings and revenue surprises of 1.52% and 0.88%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #earnings--QIAGEN reports full results for Q2 and H1 2021
Qiagen (QGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
According to QIAGEN (QGEN), stronger-than-expected growth trends were seen in non-COVID product groups in the second quarter of 2021.
Qiagen NV (NYSE: QGEN) has reported higher-than-expected second-quarter interim earnings but lowered its outlook on weaker demand for COVID-19 tests, sending its shares lower. The company expects Q2 adj...
U.S.-German genetic testing company Qiagen NV reported higher-than-expected second-quarter earnings on Monday but lowered its outlook on weaker demand for COVID-19 tests, sending its shares lower in New...
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. conference call on July 13 to discuss preliminary Q2 2021 results
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #earnings--QIAGEN announces preliminary Q2 2021 results exceeding outlook, updates full-year 2021 outlook
QIAGEN's (QGEN) NeuMoDx solutions at present offer CE-IVD tests for various viral and bacterial pathogens.
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #adenovirus--QIAGEN's NeuMoDx™ HAdV Quant Assay secures CE-IVD certification for automated testing to detect human adenovirus infections
GERMANTOWN, Md., & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #lifescience--QIAGEN launches the Workflow Configurator to help life science researchers simplify and optimize their laboratory experiments
With gradually falling COVID-19 cases, since the beginning of 2021, QIAGEN's (QGEN) COVID-19 testing related product lines are seeing significant decline in sales.
QIAGEN (QGEN) and Sysmex collaborate to develop and commercialize cancer companion diagnostics.
HILDEN, Germany & GERMANTOWN, Md. & KOBE, Japan--(BUSINESS WIRE)---- $QGEN #cdx--QIAGEN forms strategic alliance with Sysmex Corporation for global cancer companion diagnostics development and commercia...
QIAGEN's (QGEN) new collaboration will offer customers advanced tools and comprehensive support for HID workflows in laboratories.
SAN DIEGO & HILDEN, Germany & GERMAN TOWN, Md.--(BUSINESS WIRE)-- #DNAprofiling--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) and Verogen Inc. today announced a partnership to provide labora...
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #forensics--QIAGEN partners with Verogen to offer broadest portfolio for human identification, including next generation sequencing solutions
Qiagen NV (NYSE: QGEN) has launched dedicated solutions specific to CRISPR technology used for editing genomes and modifying gene function. QiaPrep&Amp CRISPR Kit and Q-Primer Solutions expand Qiagen po...
HILDEN, Germany, & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #CRISPR--QIAGEN launches dedicated CRISPR products for rapid and simplified analysis of gene-editing experiments
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
QIAGEN's (QGEN) therascreen KRAS kit to be used with LUMAKRAS is claimed to provide clinicians with a wide range of biomarker testing options, critical to patients with NSCLC.
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN #fda--QIAGEN launches first FDA-approved tissue companion diagnostic to identify the KRAS G12C mutation in NSCLC tumours
QIAGEN's (QGEN) alliance will facilitate co-development of KRAS companion diagnostic with Mirati's, adagrasib, a selective and potent oral inhibitor of KRAS G12C.
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)---- $QGEN #CDx--QIAGEN partners with Mirati Therapeutics Inc. to develop KRAS(G12C) companion diagnostic for non-small cell lung cancer (NSCLC)
QIAGEN's (QGEN) COVID-19 total antibody test processes up to 32 swab samples per hour.
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN--QIAGEN announces creation of Scientific Advisory Board and agenda for Annual General Meeting in June 2021
QIAGEN's (QGEN) QIAreach Anti-SARS-CoV-2 test takes nearly 10 minutes to detect whether a person carries antibodies to the SARS-CoV-2 virus as a result of prior infection.
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN receives U.S. FDA Emergency Use Authorization for fast and easy-to-use digital test to detect SARS-CoV-2 coronavirus antibodies
QIAGEN's (QGEN) first-quarter 2021 revenues improved year over year on strong demand for product groups addressing the critical demand for COVID-19 testing.
Qiagen NV (NYSE: QGEN) on Monday after-hours reported first-quarter revenue growth of 52% Y/Y to $567.2 million, exceeding prior guidance and beating analyst consensus by $9.68 million. Adjusted EPS $0....
Qiagen (QGEN) delivered earnings and revenue surprises of 4.76% and 2.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
U.S.-German genetic testing specialist Qiagen reported slightly better-than-expected quarterly earnings on Monday as sales growth for non-coronavirus products added to high demand for its COVID-19 testi...
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #earnings--QIAGEN exceeds outlook in first quarter 2021 results, reaffirms sales growth and profitability outlook for full-year 2021
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN announces EZ2 Connect instrument line for automated sample processing in research, forensics and diagnostics
HILDEN, Germany & SALUGGIA, Italy--(BUSINESS WIRE)--QIAGEN with DiaSorin, announce the launch of LIAISON® LymeDetect® Assay based on QuantiFERON technology for early diagnosis of Lyme Borreliosis
HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN launches artus Prep&Amp as CE-marked SARS-CoV-2 test offering up to threefold increase in daily lab testing capacity
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN N.V. to Report First Quarter 2021 Results
Investors continue to be optimistic about QIAGEN (QGEN) on the back of product launches and impressive geographical growth.
QGEN vs. TECH: Which Stock Is the Better Value Option?
Here we look at three stocks, OMI, HOLX and QGEN, that investors can add to their watchlist backed by robust long-term prospects.
QIAGEN's (QGEN) latest kit is likely to significantly reduce library turnaround times and plastics usage, thus allowing more accurate detection and quantification of molecular variants.
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN adds to COVID-19 portfolio with new ultra-fast sequencing solution for high-throughput genomic surveillance
QIAGEN's (QGEN) new NeuMoDx Flu A-B/RSV/SARS-CoV-2 Vantage test strengthens the company's portfolio in PCR testing, while becoming a crucial diagnostic tool for the flu season and the pandemic.
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN receives FDA Emergency Use Authorization for NeuMoDx multiplex test expanding COVID-19 portfolio
QIAGEN (QGEN) expands specimen types that can be used on the existing NeuMoDx SARSCoV-2 test.
QIAGEN's (QGEN) QIAsphere cloud-based platform will enhance QIAstat-Dx's potential by offering remote services round the clock to improve testing continuity.
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)---- $QGEN--QIAGEN announces 20-F annual report filing for 2020 results
About QGEN
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample mate... [Read more...]
| Industry Diagnostics & Research | IPO Date Jun 28, 1996 |
| CEO Thierry Bernard | Employees 5,750 |
| Stock Exchange NYSE | Ticker Symbol QGEN |
Analyst Forecasts
According to 13 analysts, the average rating for Qiagen stock is "Buy." The 12-month stock price forecast is 58.56, which is an increase of 10.93% from the latest price.